Stay updated with breaking news from Proportion Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
10.08.2023 - - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients ...
Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.
Immutep Limited (NASDAQ: IMMP) flew by an impressive 122% at the time of writing after positive news on their Phase II trial.
Media Release Immuno-oncology combination of eftilagimod alpha and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002... | May 17, 2023
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care... | March 31, 2023